Compare Pfizer Inc (PFE) vs Wipro Limited (WIT) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

WIT trades at $1.82, down 2.15% with bearish technical signals. The company reported mixed Q1 2027 results with revenue below expectations but maintains solid profitability with 13.92% net margin. Recent partnerships with ServiceNow and AI initiatives show strategic positioning, though earnings misses in three consecutive quarters raise execution concerns.

The stock faces headwinds from recent earnings disappointments and bearish analyst sentiment (19% buy rating), but attractive valuation (P/E 13.86) and strong cash flow generation ($169.4B operating cash flow in 2025) provide fundamental support. Key risks include client spending uncertainty and competitive pressures in IT services.